Özet:

Purpose: Extremely infectious severe acute respiratory syndrome coronavirus 2 coronavirus disease associated with acute respiratory distraction syndrome (ARDS) caused by the new coronavirus 2019 (COVID-19), is a significant cause of death during the pandemic period. Here we aim to provide a retrospective data analysis of the success of extubation for high-flow nasal oxygen (HFNO) treatment in COVID-19 ARDS patients. Tools and Methods: Data of 22 laboratory-confirmed COVID-19 ARDS patients who were extuded to HFNO treatment in the Intensive Care Unit (YBU) were analyzed. Respiratory variables and demographic characteristics were collected during the application. Measurements of blood gas with mechanical ventilation volumes and pressure were recorded during entubation. HFNO flow speed, FiO2 and oxygenation variables were collected for 5 days after extubation. In the 5 days following the planned extubation, the re-entubation rate, the stay time and mortality in the YBU were recorded. Results: 16 of the twenty-two patients were male (72.7%) and the average age was 69.9±13.2 years, with the highest comorbidity hypertension (59.1%) The period between the beginning of the symptom and the admission to the UI was 6.5±7.9 days and almost all patients were enthusiast on the same day. Twenty patients were successfully extinguished to HFNO and two patients were re-enthusiated. The average high-flow nasal oxygen treatment period is 4.8 ± 3.6 days and the stay period in intensive care is 17.4 ± 6 days. The mortality rate was 13.6 (3/22) per cent. The result: HFNO treatment should be considered in patients with high risk of ARDS COVID-19 that are applied to prevent re-entubation and post-extubation respiratory failure.

Anahtar Kelimeler: